- Patent Title: Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adranomedullin (ADM) activity by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment to the subject
-
Application No.: US15044474Application Date: 2016-02-16
-
Publication No.: US10221238B2Publication Date: 2019-03-05
- Inventor: Andreas Bergmann
- Applicant: ADRENOMED AG
- Applicant Address: DE Hennigsdorf
- Assignee: ADRENOMED AG
- Current Assignee: ADRENOMED AG
- Current Assignee Address: DE Hennigsdorf
- Agency: Millen White Zelano and Branigan, PC
- Agent John Sopp
- Priority: EP11189447 20111116; EP12160014 20120316
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/26 ; G01N33/68 ; A61K31/137 ; A61K38/22 ; A61K39/00 ; A61K45/06
Abstract:
Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.
Public/Granted literature
Information query
